Quantification of Anti-Ro52, Anti-Ro60 and Anti-La Autoantibodies at High Sample Dilution and Their Predictive Value for Congenital Heart Block.
4 affiliations
- 1Division of Rheumatology, Department of Medicine, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.
- 2Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
- 3Pediatric Cardiology Unit, Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
- 4Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
Abstract
Maternal anti-Ro/La antibodies confer a risk of congenital heart block (CHB), but current methods for predicting risk relying on the presence or absence of these autoantibodies perform poorly. To identify more accurate biomarkers of CHB risk, we investigated the association between maternal levels of autoantibodies and the risk of CHB. A total of 318 women positive for anti-Ro/SSA autoantibodies were included. Autoantibody presence was obtained from health records for all, and ELISA was used to quantify levels of anti-Ro52, anti-Ro60, and anti-La in a subset of 116 women with samples obtained during pregnancy, including 27 CHB-affected pregnancies. Predictive models for CHB risk were developed using logistic regression and machine learning. Anti-Ro/SSA positive women with anti-Ro60 were more likely to have pregnancies with CHB (p < 0.05). Levels of both anti-Ro60 (p < 0.001) and anti-Ro52 (p < 0.05) were significantly higher in CHB-affected pregnancies and correlated (r = 0.8, p < 0.0001), while levels of anti-La did not differ between groups. Levels of anti-Ro60 were identified as the strongest individual predictor of CHB, with a relative risk of 16.3 (95% CI 1.04-255.0, p < 0.001) for the top versus the bottom decile. In all tested combinations, models that included anti-Ro60 levels outperformed models that did not. Models based on anti-Ro60 levels alone reached an area under the curve (AUC) of 0.76 and an odds ratio (OR) per standard deviation increase of 2.8 (95% CI 1.6-5.3). These findings confirm a strong association between maternal anti-Ro antibody levels and CHB risk in anti-SSA-positive pregnancy, highlighting anti-Ro60 autoantibody levels as a valuable biomarker in risk stratification.
Related
- Predictive autoantibodies before the diagnosis of type I diabetes in adults
- Interlaboratory comparison of immunoprecipitation-based testing for myositis-specific autoantibodies
- Highly neutralizing anti–IFN-ω autoantibodies underlie severe pediatric adenovirus infection
- MAKAAO, an open access resource linking human autoantibodies and autoimmune diseases
- Selectivity Dilution in Three-Factor Learning: A Finite-Population Model with Potential Implications for Motor Development and Post-Stroke Motor Rehabilitation
BibTeX
@article{rudolph2026quantification,
title = {{Quantification of Anti-Ro52, Anti-Ro60 and Anti-La Autoantibodies at High Sample Dilution and Their Predictive Value for Congenital Heart Block.}},
author = {Lisa Rudolph and Elina Richardsdotter Möller and Rui Da Silva Rodrigues and Gregoire Martin de Fremont and Vijole Ottosson and Linda Lagnefeld and Iva Gunnarsson and Elisabet Svenungsson and Felicia Nordenstam and Gunnar Bergman and Sven-Erik Sonesson and Gudny Ella Thorlacius and Marie Wahren-Herlenius},
journal = {Scandinavian journal of immunology},
year = {2026},
month = nov,
doi = {10.1111/sji.70164},
url = {https://europepmc.org/article/MED/42975002},
note = {CC BY},
}
RIS
TY - JOUR
TI - Quantification of Anti-Ro52, Anti-Ro60 and Anti-La Autoantibodies at High Sample Dilution and Their Predictive Value for Congenital Heart Block.
AU - Lisa Rudolph
AU - Elina Richardsdotter Möller
AU - Rui Da Silva Rodrigues
AU - Gregoire Martin de Fremont
AU - Vijole Ottosson
AU - Linda Lagnefeld
AU - Iva Gunnarsson
AU - Elisabet Svenungsson
AU - Felicia Nordenstam
AU - Gunnar Bergman
AU - Sven-Erik Sonesson
AU - Gudny Ella Thorlacius
AU - Marie Wahren-Herlenius
PY - 2026
DA - 2026/11/01
JO - Scandinavian journal of immunology
DO - 10.1111/sji.70164
UR - https://europepmc.org/article/MED/42975002
AB - Maternal anti-Ro/La antibodies confer a risk of congenital heart block (CHB), but current methods for predicting risk relying on the presence or absence of these autoantibodies perform poorly. To identify more accurate biomarkers of CHB risk, we investigated the association between maternal levels of autoantibodies and the risk of CHB. A total of 318 women positive for anti-Ro/SSA autoantibodies were included. Autoantibody presence was obtained from health records for all, and ELISA was used to quantify levels of anti-Ro52, anti-Ro60, and anti-La in a subset of 116 women with samples obtained during pregnancy, including 27 CHB-affected pregnancies. Predictive models for CHB risk were developed using logistic regression and machine learning. Anti-Ro/SSA positive women with anti-Ro60 were more likely to have pregnancies with CHB (p < 0.05). Levels of both anti-Ro60 (p < 0.001) and anti-Ro52 (p < 0.05) were significantly higher in CHB-affected pregnancies and correlated (r = 0.8, p < 0.0001), while levels of anti-La did not differ between groups. Levels of anti-Ro60 were identified as the strongest individual predictor of CHB, with a relative risk of 16.3 (95% CI 1.04-255.0, p < 0.001) for the top versus the bottom decile. In all tested combinations, models that included anti-Ro60 levels outperformed models that did not. Models based on anti-Ro60 levels alone reached an area under the curve (AUC) of 0.76 and an odds ratio (OR) per standard deviation increase of 2.8 (95% CI 1.6-5.3). These findings confirm a strong association between maternal anti-Ro antibody levels and CHB risk in anti-SSA-positive pregnancy, highlighting anti-Ro60 autoantibody levels as a valuable biomarker in risk stratification.
SN - 0300-9475
SN - 1365-3083
ER -